Alkermes plc. Contract with Customer, Asset, Reclassified to Receivable
Alkermes plc. (ALKS) reported Contract with Customer, Asset, Reclassified to Receivable of $9.47 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes
us-gaap:ContractWithCustomerAssetReclassifiedToReceivable · last filed 2026-02-25
- Alkermes plc. contract with customer, asset, reclassified to receivable for the quarter ending 2025-12-31 was $717.00K.
- Alkermes plc. contract with customer, asset, reclassified to receivable for the quarter ending 2025-09-30 was $1.42M, a 33.64% decline year-over-year.
- Alkermes plc. contract with customer, asset, reclassified to receivable for the quarter ending 2025-06-30 was $2.34M, a 90.56% increase year-over-year.
- Alkermes plc. contract with customer, asset, reclassified to receivable for the quarter ending 2025-03-31 was $4.99M, a 606.80% increase year-over-year.
- Alkermes plc. contract with customer, asset, reclassified to receivable for fiscal 2025 was $9.47M, a 306.39% increase from fiscal 2024.
- Alkermes plc. contract with customer, asset, reclassified to receivable for fiscal 2024 was $2.33M, a 89.32% decline from fiscal 2023.
- Alkermes plc. contract with customer, asset, reclassified to receivable for fiscal 2023 was $21.83M, a 53.21% decline from fiscal 2022.
- Alkermes plc. contract with customer, asset, reclassified to receivable for fiscal 2022 was $46.65M, a 27.30% increase from fiscal 2021.
| Period end | Contract with Customer, Asset, Reclassified to Receivable 3 month | Contract with Customer, Asset, Reclassified to Receivable 6 month | Contract with Customer, Asset, Reclassified to Receivable 9 month | Contract with Customer, Asset, Reclassified to Receivable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $717.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.14M derived: sum of 2 quarters · filed 2026-02-25 | $4.48M derived: sum of 3 quarters · filed 2026-02-25 | $9.47M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $3.77M derived: sum of 2 quarters · filed 2025-10-28 | $8.76M 10-Q · filed 2025-10-28 | $7.01M derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $7.33M 10-Q · filed 2025-07-29 | $5.58M derived: sum of 3 quarters · filed 2026-02-25 | $7.73M derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-03-31 | $4.99M 10-Q · filed 2025-05-01 | $3.24M derived: sum of 2 quarters · filed 2026-02-25 | $5.39M derived: sum of 3 quarters · filed 2026-02-25 | $6.62M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $396.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.63M derived: sum of 3 quarters · filed 2026-02-25 | $2.33M 10-K · filed 2026-02-25 |
| 2024-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-24 | $3.38M derived: sum of 2 quarters · filed 2024-10-24 | $4.08M 10-Q · filed 2024-10-24 | $6.87M derived: sum of 4 quarters · filed 2025-02-12 |
| 2024-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | $1.94M 10-Q · filed 2024-07-24 | $4.72M derived: sum of 3 quarters · filed 2025-02-12 | $4.72M derived: sum of 4 quarters · filed 2025-02-12 |
| 2024-03-31 | $706.00K 10-Q · filed 2024-05-01 | $3.49M derived: sum of 2 quarters · filed 2025-02-12 | $3.49M derived: sum of 3 quarters · filed 2025-02-12 | $11.92M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $2.79M derived: sum of 2 quarters · filed 2025-02-12 | $11.21M derived: sum of 3 quarters · filed 2025-02-12 | $21.83M 10-K · filed 2025-02-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | $8.43M derived: sum of 2 quarters · filed 2023-10-25 | $19.04M 10-Q · filed 2023-10-25 | $32.22M derived: sum of 4 quarters · filed 2024-02-21 |
| 2023-06-30 | $8.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | $19.04M 10-Q · filed 2023-07-26 | $32.22M derived: sum of 3 quarters · filed 2024-02-21 | $46.94M derived: sum of 4 quarters · filed 2024-02-21 |
| 2023-03-31 | $10.62M 10-Q · filed 2023-04-26 | $23.79M derived: sum of 2 quarters · filed 2024-02-21 | $38.51M derived: sum of 3 quarters · filed 2024-02-21 | $52.66M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-12-31 | $13.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $27.89M derived: sum of 2 quarters · filed 2024-02-21 | $42.05M derived: sum of 3 quarters · filed 2024-02-21 | $46.65M 10-K · filed 2024-02-21 |
| 2022-09-30 | $14.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $28.87M derived: sum of 2 quarters · filed 2022-11-02 | $33.47M 10-Q · filed 2022-11-02 | $36.84M derived: sum of 4 quarters · filed 2023-02-16 |
| 2022-06-30 | $14.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $18.76M 10-Q · filed 2022-07-27 | $22.13M derived: sum of 3 quarters · filed 2023-02-16 | $31.65M derived: sum of 4 quarters · filed 2023-02-16 |
| 2022-03-31 | $4.60M 10-Q · filed 2022-04-27 | $7.97M derived: sum of 2 quarters · filed 2023-02-16 | $17.49M derived: sum of 3 quarters · filed 2023-02-16 | $27.34M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $12.89M derived: sum of 2 quarters · filed 2023-02-16 | $22.74M derived: sum of 3 quarters · filed 2023-02-16 | $36.65M 10-K · filed 2023-02-16 |
| 2021-09-30 | $9.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $19.37M derived: sum of 2 quarters · filed 2021-10-27 | $33.28M 10-Q · filed 2021-10-27 | $43.03M derived: sum of 4 quarters · filed 2022-02-16 |
| 2021-06-30 | $9.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $23.76M 10-Q · filed 2021-07-28 | $33.51M derived: sum of 3 quarters · filed 2022-02-16 | $42.73M derived: sum of 4 quarters · filed 2022-02-16 |
| 2021-03-31 | $13.91M 10-Q · filed 2021-04-28 | $23.66M derived: sum of 2 quarters · filed 2022-02-16 | $32.87M derived: sum of 3 quarters · filed 2022-02-16 | $45.88M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-12-31 | $9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $18.96M derived: sum of 2 quarters · filed 2022-02-16 | $31.98M derived: sum of 3 quarters · filed 2022-02-16 | $40.31M 10-K · filed 2022-02-16 |
| 2020-09-30 | $9.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $22.23M derived: sum of 2 quarters · filed 2020-10-29 | $30.56M 10-Q · filed 2020-10-29 | $35.60M derived: sum of 4 quarters · filed 2021-02-11 |
| 2020-06-30 | $13.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $21.34M 10-Q · filed 2020-07-29 | $26.39M derived: sum of 3 quarters · filed 2021-02-11 | $38.73M derived: sum of 4 quarters · filed 2021-02-11 |
| 2020-03-31 | $8.33M 10-Q · filed 2020-04-29 | $13.37M derived: sum of 2 quarters · filed 2021-02-11 | $25.72M derived: sum of 3 quarters · filed 2021-02-11 | $33.96M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-12-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $17.39M derived: sum of 2 quarters · filed 2021-02-11 | $25.63M derived: sum of 3 quarters · filed 2021-02-11 | $32.76M 10-K · filed 2021-02-11 |
| 2019-09-30 | $12.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-23 | $20.59M derived: sum of 2 quarters · filed 2019-10-23 | $27.71M 10-Q · filed 2019-10-23 | |
| 2019-06-30 | $8.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $15.37M 10-Q · filed 2019-07-25 | ||
| 2019-03-31 | $7.13M 10-Q · filed 2019-04-25 | |||
| 2018-12-31 | $58.50M 10-K · filed 2020-02-13 | |||
| 2018-09-30 | $45.02M 10-Q · filed 2018-10-23 | |||
| 2018-06-30 | $25.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $32.89M 10-Q · filed 2018-07-26 | ||
| 2018-03-31 | $6.92M 10-Q · filed 2018-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |